1. Home
  2. CSTL vs FFIC Comparison

CSTL vs FFIC Comparison

Compare CSTL & FFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSTL
  • FFIC
  • Stock Information
  • Founded
  • CSTL 2007
  • FFIC 1929
  • Country
  • CSTL United States
  • FFIC United States
  • Employees
  • CSTL N/A
  • FFIC N/A
  • Industry
  • CSTL Medical Specialities
  • FFIC Major Banks
  • Sector
  • CSTL Health Care
  • FFIC Finance
  • Exchange
  • CSTL Nasdaq
  • FFIC Nasdaq
  • Market Cap
  • CSTL 456.2M
  • FFIC 401.3M
  • IPO Year
  • CSTL 2019
  • FFIC 1995
  • Fundamental
  • Price
  • CSTL $20.30
  • FFIC $12.73
  • Analyst Decision
  • CSTL Strong Buy
  • FFIC Hold
  • Analyst Count
  • CSTL 6
  • FFIC 3
  • Target Price
  • CSTL $37.67
  • FFIC $16.17
  • AVG Volume (30 Days)
  • CSTL 451.0K
  • FFIC 251.8K
  • Earning Date
  • CSTL 08-04-2025
  • FFIC 07-24-2025
  • Dividend Yield
  • CSTL N/A
  • FFIC 6.91%
  • EPS Growth
  • CSTL N/A
  • FFIC N/A
  • EPS
  • CSTL N/A
  • FFIC N/A
  • Revenue
  • CSTL $347,083,000.00
  • FFIC $124,028,000.00
  • Revenue This Year
  • CSTL N/A
  • FFIC $112.30
  • Revenue Next Year
  • CSTL $1.36
  • FFIC $7.61
  • P/E Ratio
  • CSTL N/A
  • FFIC N/A
  • Revenue Growth
  • CSTL 38.43
  • FFIC N/A
  • 52 Week Low
  • CSTL $15.45
  • FFIC $10.65
  • 52 Week High
  • CSTL $35.84
  • FFIC $18.59
  • Technical
  • Relative Strength Index (RSI)
  • CSTL 66.24
  • FFIC 63.05
  • Support Level
  • CSTL $18.18
  • FFIC $11.80
  • Resistance Level
  • CSTL $20.63
  • FFIC $12.60
  • Average True Range (ATR)
  • CSTL 0.78
  • FFIC 0.36
  • MACD
  • CSTL 0.15
  • FFIC 0.13
  • Stochastic Oscillator
  • CSTL 87.97
  • FFIC 97.08

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About FFIC Flushing Financial Corporation

Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.

Share on Social Networks: